Argus Trims CVS Health (CVS) PT to $90 Amid Medicare Advantage Rate Uncertainty

CVS Health Corporation (NYSE:CVS) is one of the most undervalued large cap stocks to invest in now. On January 28, Argus reduced its price target for CVS Health to $90 from $91 while maintaining a Buy rating. Despite a nearly 15% stock decline following the Centers for Medicare and Medicaid Services’ proposal for a flat 2027 Medicare Advantage reimbursement rate, the firm anticipates an upward revision before the final rate is set in April 2026. Argus suggested that even if the final increase falls short o ...